Efficacy and safety of Gelsectan for diarrhoea‐predominant irritable bowel syndrome: A randomised, crossover clinical trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Irritable bowel syndrome (IBS) is highly prevalent and presents a clinical challenge. Gelsectan is a medical device containing xyloglucan (XG), pea protein and tannins (PPT) from grape seed extract, and xylo‐oligosaccharides (XOS), which act together to protect and reinforce the intestinal barrier. Objective: The objective of this study is to evaluate the efficacy and safety of XG + PPT + XOS in patients with diarrhoea‐predominant IBS (IBS‐D). Methods: In this double‐blind study, 60 patients were randomly assigned to receive XG + PPT + XOS or placebo for 28 days, then crossed over to the alternative treatment. Patients were followed for 60 days. Results: At Day 28, a significantly higher proportion of patients starting treatment with XG + PPT + XOS than placebo (87 vs 0%; p = 0.0019) presented normal stools (Bristol Stool Form Scale type 3−4). At Day 56, a significantly higher proportion of patients who crossed over to XG + PPT + XOS than placebo (93% vs 23%; p = 0.0001) presented normal stools. In the group allocated to receive XG + PPT + XOS after placebo, benefits of XG + PPT + XOS were maintained during follow‐up. Subjective assessments of abdominal pain, bloating, quality of life and general health indicated significant improvement with XG + PPT + XOS over placebo. There were no related adverse events. Conclusion: XG + PPT + XOS effectively controlled diarrhoea and alleviated clinical symptoms in patients with IBS‐D, and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine
Saha, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6759 · Cited by 500
Blake, M. R., Raker, J. M., & Whelan, K. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13746 · Cited by 495
Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota
Finegold, S. M., Li, Z., Summanen, P. H., Downes, J., Thames, G., Corbett, K., Dowd, S., Krak, M., & Heber, D. (2014) · Food & Function · doi:10.1039/c3fo60348b · Cited by 255
Cited by
Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier
Barbara, G., Barbaro, M. R., Fuschi, D., Palombo, M., Falangone, F., Cremon, C., Marasco, G., & Stanghellini, V. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.718356 · Cited by 403
Diagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
Savarino, E., Zingone, F., Barberio, B., Marasco, G., Akyuz, F., Akpinar, H., Barboi, O., Bodini, G., Bor, S., Chiarioni, G., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12259 · Cited by 146
Impact of diet on symptoms of the irritable bowel syndrome
Spiller, R. (2021) · Nutrients · doi:10.3390/nu13020575 · Cited by 86
“A more recent study using a combination of xyloglucan and pea protein and grape tannins supports the idea that enhancing barrier function might be therapeutic in IBS-D patients [27].”
Background
Metadata
- Authors
- Trifan, A., Burta, O., Tiuca, N., Petrisor, D. C., Lenghel, A., & Santos, J.
- Venue
- United European Gastroenterology Journal
- Publisher
- Wiley
- Published
- 2019-10
- Volume
- 7
- Issue
- 8
- Pages
- 1093-1101
- ISSN
- 2050-6406 (ISSN-L)
- 2050-6414
- OpenAlex
- W2956126375
- Cited by
- 55
- References
- 5
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of Gelsectan for diarrhoea‐predominant irritable bowel syndrome: A randomised, crossover clinical trial. https://app.cochat.ai/papers/10.1177/2050640619862721
- The paper
- Trifan, A., Burta, O., Tiuca, N., Petrisor, D. C., Lenghel, A., & Santos, J. (2019). Efficacy and safety of Gelsectan for diarrhoea‐predominant irritable bowel syndrome: A randomised, crossover clinical trial. United European Gastroenterology Journal. https://doi.org/10.1177/2050640619862721
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.